MCID: CRN020
MIFTS: 34

Coronary Restenosis

Categories: Cardiovascular diseases

Aliases & Classifications for Coronary Restenosis

MalaCards integrated aliases for Coronary Restenosis:

Name: Coronary Restenosis 12 56 45 15 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:4247
MeSH 45 D023903
UMLS 74 C0948480

Summaries for Coronary Restenosis

MalaCards based summary : Coronary Restenosis is related to angina pectoris and coronary artery anomaly. An important gene associated with Coronary Restenosis is ACE (Angiotensin I Converting Enzyme). The drugs Celecoxib and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and t cells, and related phenotypes are Decreased viability in esophageal squamous lineage and cardiovascular system

Related Diseases for Coronary Restenosis

Graphical network of the top 20 diseases related to Coronary Restenosis:



Diseases related to Coronary Restenosis

Symptoms & Phenotypes for Coronary Restenosis

GenomeRNAi Phenotypes related to Coronary Restenosis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.1 ADRA2B CDKN2A FABP4 ITGA4 LMOD1 SERPINC1

MGI Mouse Phenotypes related to Coronary Restenosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.43 ACE ADRA2B CDKN2A FABP4 ITGA4 SERPINC1
2 liver/biliary system MP:0005370 8.92 ACE CDKN2A FABP4 SERPINC1

Drugs & Therapeutics for Coronary Restenosis

Drugs for Coronary Restenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 5284616 6436030
5
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 70789204 6442177
6
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 33069-62-4 36314
7
Probucol Approved, Investigational Phase 4 23288-49-5 4912
8
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
9
Polyestradiol phosphate Approved Phase 4 28014-46-2
10
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
11
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
12
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
13
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
14
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
15 Analgesics Phase 4
16 Antirheumatic Agents Phase 4
17 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
18 Peripheral Nervous System Agents Phase 4
19 Cyclooxygenase 2 Inhibitors Phase 4
20 Cyclooxygenase Inhibitors Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4
23 Epoetin alfa Phase 4 113427-24-0
24 Hematinics Phase 4
25 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Angiogenesis Inhibitors Phase 4
27 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Angiogenesis Modulating Agents Phase 4
29 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Platelet Aggregation Inhibitors Phase 4
32 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Albumin-Bound Paclitaxel Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Protective Agents Phase 4
38 Hypolipidemic Agents Phase 4
39 Lipid Regulating Agents Phase 4
40 Antimetabolites Phase 4
41 Anticholesteremic Agents Phase 4
42 Antioxidants Phase 4,Phase 2,Phase 3
43 Technetium Tc 99m Sestamibi Phase 4
44 Radiopharmaceuticals Phase 4
45 Hormones Phase 4
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
47 Estradiol 3-benzoate Phase 4
48 Estradiol 17 beta-cypionate Phase 4
49 Estrogens Phase 4
50 Hormone Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions Unknown status NCT02300454 Phase 4
2 SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents Unknown status NCT00714545 Phase 4
3 Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial Unknown status NCT00500279 Phase 4 Celecoxib
4 Anti-Restenosis After AMI by Erythropoietin Unknown status NCT00423020 Phase 4 Erythropoietin
5 Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation Unknown status NCT01638078 Phase 4 Thalidomide;Placebo
6 Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside) Unknown status NCT00963781 Phase 4 Reduced duration (6 months) DAPT
7 Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis Completed NCT00598533 Phase 4
8 Cost-Effectiveness Study in the Reduction of Coronary Restenosis With Sirolimus-Eluting Stents Completed NCT00627900 Phase 4
9 Oral Sirolimus for In-Stent Restenosis Completed NCT00859183 Phase 4 Sirolimus;Sirolimus;Placebo
10 Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de Novo Coronary Lesions (PAINT) Completed NCT00752362 Phase 4
11 Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty Completed NCT00162357 Phase 4 Technetium Tc99m Sestamibi
12 The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis Completed NCT00332397 Phase 4
13 Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents Completed NCT00598715 Phase 4
14 Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents Completed NCT00552669 Phase 4 Oral sirolimus
15 Rapamycin+Estradiol- vs. Rapamycin-Eluting Stents to Reduce Restenosis (ISAR-PEACE) Completed NCT00402636 Phase 4
16 Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis (ISAR-TEST-3) Completed NCT00350454 Phase 4
17 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study) Completed NCT01171820 Phase 4
18 SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe Completed NCT00402272 Phase 4
19 Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes Completed NCT00599885 Phase 4 telmisartan;valsartan
20 EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease Completed NCT00531011 Phase 4
21 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente Completed NCT01066650 Phase 4
22 XIENCE V: SPIRIT WOMEN Sub-study Completed NCT01182428 Phase 4
23 XIENCE V: SPIRIT WOMEN Completed NCT00496938 Phase 4
24 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population Completed NCT01331707 Phase 4
25 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) Completed NCT01178268 Phase 4
26 XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort Completed NCT01106534 Phase 4 placebo + aspirin;clopidogrel + aspirin OR prasugrel + aspirin
27 Study of the Xience V Everolimus-eluting Stent in Saphenous Vein Graft Lesions Completed NCT00911976 Phase 4
28 Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis Terminated NCT01967199 Phase 4
29 Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation Unknown status NCT00426049 Phase 3 Everolimus
30 PIoglitazone for PrEvention of Restenosis in Diabetic Patients Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
31 Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period Completed NCT00882219 Phase 3
32 Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis Completed NCT00287573 Phase 2, Phase 3
33 A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels. Completed NCT00055510 Phase 2, Phase 3 BO-653
34 SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System Completed NCT00180310 Phase 3
35 Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries Completed NCT00148356 Phase 2, Phase 3
36 BioFreedom FIM Clinical Trial. Completed NCT01172119 Phase 2, Phase 3
37 SPIRIT PRIME Clinical Trial Completed NCT00916370 Phase 3
38 SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System Completed NCT00307047 Phase 3
39 The SOS (Stenting Of Saphenous Vein Grafts) Trial Completed NCT00247208 Phase 3
40 SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) Completed NCT00180479 Phase 3
41 Treatment of In-Stent Restenosis 2 Study Recruiting NCT03667313 Phase 3
42 Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon Recruiting NCT03242096 Phase 2, Phase 3
43 The Effects of Bindarit in Preventing Stent Restenosis Completed NCT01269242 Phase 2 bindarit;bindarit;placebo
44 Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR II) Completed NCT00409981 Phase 1, Phase 2
45 Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis Completed NCT00124943 Phase 1, Phase 2 Nanoparticle Paclitaxel
46 Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR I) Completed NCT00106587 Phase 1, Phase 2
47 OCT Evaluation of Healing of COMBO Stent Completed NCT01274234 Phase 1, Phase 2
48 Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries Completed NCT00248066 Phase 2 RESTEN-MP
49 Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries Completed NCT00140101 Phase 2
50 Serp-1 for the Treatment of Acute Coronary Syndrome Terminated NCT00243308 Phase 2 Serine proteinase-1 (Serp-1)

Search NIH Clinical Center for Coronary Restenosis

Cochrane evidence based reviews: coronary restenosis

Genetic Tests for Coronary Restenosis

Anatomical Context for Coronary Restenosis

MalaCards organs/tissues related to Coronary Restenosis:

42
Endothelial, Liver, T Cells, Testes, Smooth Muscle, Monocytes, Heart

Publications for Coronary Restenosis

Articles related to Coronary Restenosis:

(show top 50) (show all 179)
# Title Authors Year
1
Coronary restenosis of in-stent protruding bump with rapid progression: Optical frequency domain imaging and angioscopic observation. ( 30693051 )
2019
2
Five-year follow-up of the endothelial progenitor cell capturing stent versus the paxlitaxel-eluting stent in de novo coronary lesions with a high risk of coronary restenosis. ( 28868810 )
2018
3
Third generation dual-source CT enables accurate diagnosis of coronary restenosis in all size stents with low radiation dose and preserved image quality. ( 29349698 )
2018
4
Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease. ( 29716394 )
2018
5
Associations between endothelial progenitor cells, clinical characteristics and coronary restenosis in patients undergoing percutaneous coronary artery intervention. ( 29739448 )
2018
6
Anti-Inflammatory Effect of Gallic Acid-Eluting Stent in a Porcine Coronary Restenosis Model. ( 29844643 )
2018
7
miR-196a2 (rs11614913) polymorphism is associated with coronary artery disease, but not with in-stent coronary restenosis. ( 30560371 )
2018
8
Effect of Stents Coated with Artemisinin or Dihydroartemisinin in a Porcine Coronary Restenosis Model. ( 28154599 )
2017
9
The Control of Drug Release and Vascular Endothelialization after Hyaluronic Acid-Coated Paclitaxel Multi-Layer Coating Stent Implantation in Porcine Coronary Restenosis Model. ( 28154600 )
2017
10
Drug- and Gene-eluting Stents for Preventing Coronary Restenosis. ( 28184335 )
2017
11
Recurrent coronary restenosis treated with Chinese medicine: A case report. ( 28861805 )
2017
12
Combination of drug-coated balloon angioplasty and excimer laser coronary angioplasty ablation for coronary restenosis of Kawasaki disease: A case report. ( 30524575 )
2017
13
Stent linker effect in a porcine coronary restenosis model. ( 26318568 )
2016
14
Association between cholesterol efflux capacity and coronary restenosis after successful stent implantation. ( 26337618 )
2016
15
Effect of stents coated with a combination of sirolimus and alpha-lipoic acid in a porcine coronary restenosis model. ( 26886814 )
2016
16
A novel polymer-free drug-eluting stent coated with everolimus using nitrogen-doped titanium dioxide film deposition in a porcine coronary restenosis model. ( 27505330 )
2016
17
Impact of Angiographic Result After Predilatation on Outcome After Drug-Coated Balloon Treatment of In-Stent Coronary Restenosis. ( 27634028 )
2016
18
Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial). ( 27634828 )
2016
19
Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model. ( 27976797 )
2016
20
Effect of pretreatment of ezetimibe/simvastatin on arterial healing and endothelialization after drug-eluting stent implantation in a porcine coronary restenosis model. ( 25810732 )
2015
21
Controlled Slow-Release Drug-Eluting Stents for the Prevention of Coronary Restenosis: Recent Progress and Future Prospects. ( 26011753 )
2015
22
Association of ACE insertion or deletion polymorphisms with the risk of coronary restenosis after percutaneous coronary intervention: A meta-analysis. ( 26195267 )
2015
23
Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. ( 24465275 )
2014
24
Effect of polymer-free TiO2 stent coated with abciximab or alpha lipoic acid in porcine coronary restenosis model. ( 24852847 )
2014
25
A micro RNA-146a polymorphism is associated with coronary restenosis. ( 25053223 )
2014
26
Pharmacological inhibition of coronary restenosis: systemic and local approaches. ( 25145263 )
2014
27
Regular exercise training reduces coronary restenosis after percutaneous coronary intervention in patients with acute myocardial infarction. ( 22795710 )
2013
28
Two-dimensional fluorescence in-gel electrophoresis of coronary restenosis tissues in minipigs: increased adipocyte fatty acid binding protein induces reactive oxygen species-mediated growth and migration in smooth muscle cells. ( 23372061 )
2013
29
Mechanical and Histopathological Comparison between Commercialized and Newly Designed Coronary Bare Metal Stents in a Porcine Coronary Restenosis Model. ( 23678471 )
2013
30
Pathway analysis using genome-wide association study data for coronary restenosis--a potential role for the PARVB gene. ( 23950981 )
2013
31
Genetic polymorphism of angiotensin converting enzyme and risk of coronary restenosis after percutaneous transluminal coronary angioplasties: evidence from 33 cohort studies. ( 24098690 )
2013
32
Influence of the angiotensin converting enzyme insertion or deletion genetic variant and coronary restenosis risk: evidence based on 11,193 subjects. ( 24349507 )
2013
33
Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model. ( 24363750 )
2013
34
Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention. ( 22454659 )
2012
35
Systematic testing of literature reported genetic variation associated with coronary restenosis: results of the GENDER Study. ( 22879966 )
2012
36
Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. ( 21301785 )
2011
37
Coronary restenosis and contact allergy to stent material. ( 21608294 )
2011
38
Effect of a dual drug-coated stent with abciximab and alpha-lipoic Acid in a porcine coronary restenosis model. ( 21731564 )
2011
39
Effects of ramiprilat-coated stents on neointimal hyperplasia, inflammation, and arterial healing in a porcine coronary restenosis model. ( 22022329 )
2011
40
Drug-eluting stent as an option for intractable in-stent coronary restenosis. ( 22194765 )
2011
41
The association between epicardial fat thickness in echocardiography and coronary restenosis in drug eluting stents. ( 22577439 )
2011
42
Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. ( 19933225 )
2010
43
Right-sided chest leads in exercise testing for detection of coronary restenosis. ( 20162735 )
2010
44
Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. ( 20226618 )
2010
45
Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent implantation in a porcine coronary restenosis model. ( 20436707 )
2010
46
Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. ( 20834185 )
2010
47
Lack of association between the cholesteryl ester transfer protein gene--TaqIB polymorphism and coronary restenosis following percutaneous transluminal coronary angioplasty and stenting: a pilot study. ( 19815603 )
2010
48
Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. ( 19962471 )
2009
49
In-stent coronary restenosis, but not the type of stent, is associated with impaired endothelial-dependent vasodilatation. ( 19253185 )
2009
50
Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. ( 19280084 )
2009

Variations for Coronary Restenosis

Expression for Coronary Restenosis

Search GEO for disease gene expression data for Coronary Restenosis.

Pathways for Coronary Restenosis

GO Terms for Coronary Restenosis

Cellular components related to Coronary Restenosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.02 ACE CETP FABP4 ITGA4 SERPINC1

Biological processes related to Coronary Restenosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cholesterol homeostasis GO:0042632 9.26 CETP FABP4
2 negative regulation of protein kinase activity GO:0006469 9.16 CDKN2A FABP4
3 regulation of vasoconstriction GO:0019229 8.96 ACE ADRA2B
4 positive regulation of blood pressure GO:0045777 8.62 ACE ADRA2B

Sources for Coronary Restenosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....